CD40 and lung cancer: In mouse and human lung cancer models, seven populations of neutrophils were identified, and CD40 agonist antibody treatment increased immune response by more than 10-fold in both N1a (Sellhi Ngphi) and N2 (Sellhi Cxcl10hi) neutrophil populations, characterized by high expression of interferon-stimulated genes (ISGs) [54].